catalystpsychiatry.com Open in urlscan Pro
45.79.113.234  Public Scan

Form analysis
0 forms found in the DOM

Text Content

We’ve moved! Our new address is 2222 NW Lincoln Ave., Corvallis, OR .
 * (541) 730-4400
 * Patient Portal

 * TMS Self Assessment

 * Services
   * Counseling
   * Deep TMS
   * GeneSight
   * Medication Management
   * Psychiatric Diagnosis & Treatment
   * Psychotherapy
 * Physicians & Staff
 * Careers
 * Contact

Menu
 * Services
   * Counseling
   * Deep TMS
   * GeneSight
   * Medication Management
   * Psychiatric Diagnosis & Treatment
   * Psychotherapy
 * Physicians & Staff
 * Careers
 * Contact


DISCOVER SPRAVATO®


IT’S THE FIRST FDA-APPROVED NASAL SPRAY SPECIFICALLY FOR ADULTS WITH
TREATMENT-RESISTANT DEPRESSION.

Ask your healthcare provider if SPRAVATO® may be right for you.


"Allison’s son tried many oral antidepressants without relief. Now, because of
SPRAVATO®, Allison’s son is starting to feel like himself again. "
Allison
Mother of real patient with treatment-resistent depression
See Full Prescribing Info


IF YOU STRUGGLE WITH TREATMENT-RESISTANT DEPRESSION, THERE'S A DIFFERENT CHOICE
TO TURN TO.

If you’ve tried two or more antidepressants of adequate dose and duration and
are still struggling with depressive symptoms, talk to your healthcare provider
to see if you may have treatment-resistant depression. SPRAVATO® works
differently than other medications for treatment-resistant depression. Today’s
most commonly used oral antidepressants are thought to treat depression by
increasing levels of neurotransmitters (serotonin, norepinephrine and dopamine)
in areas of the brain that affect mood. SPRAVATO® targets the
N-methyl-D-aspartate (NMDA) receptor and is believed to work differently than
currently available oral antidepressants. The exact way that SPRAVATO® works is
unknown. SPRAVATO® is taken with an oral antidepressant.

Contact Us Today


SPRAVATO® WAS PROVEN EFFECTIVE FOR ADULTS WITH TREATMENT-RESISTANT DEPRESSION
WHEN TAKEN WITH AN ORAL ANTIDEPRESSANT.

In a short-term clinical study of adults with treatment-resistant depression,*
those who took SPRAVATO® and an oral antidepressant experienced a greater
reduction of depression symptoms at four weeks† (compared to those who received
a placebo and an oral antidepressant).

In a long-term study after 16 weeks of therapy, patients who stayed on
SPRAVATO®‡ were less likely to experience a return of depressive symptoms than
those who stopped therapy.

*Adults with major depressive disorder who have not responded sufficiently to at
least two different antidepressants of adequate dose and duration in the current
episode. † Based on an overall score on a standardized rating scale. ‡ Along
with an oral antidepressant.

Download the Brochure


SPRAVATO® IS ALSO FDA-APPROVED FOR MAJOR DEPRESSIVE DISORDER WITH SUICIDAL
IDEATION.

In studies of patients with major depressive disorder and active suicidal
thoughts or actions, those who took and an oral antidepressant experienced a
greater reduction of depressive symptoms at 24 hours compared to those who
received a placebo plus an oral antidepressant.* Further reductions were seen
consistently through four weeks (25 days) of treatment, so it is important to
follow the treatment plan that you and your healthcare provider have made. Not
all patients will respond to SPRAVATO®.

It is not known if SPRAVATO® is safe and effective for use in preventing suicide
or in reducing suicidal thoughts or actions. SPRAVATO® is not for use in place
of hospitalization if your healthcare provider determines that hospitalization
is needed, even if improvement is experienced after the first dose of SPRAVATO®.

Ask your healthcare provider if SPRAVATO® may be right for you. SPRAVATO® is not
for use as a medicine to prevent or relieve pain (anesthetic). It is not known
if SPRAVATO® is safe or effective as an anesthetic medicine. It is not known if
SPRAVATO® is safe and effective in children.

Please see Important Safety Information in this brochure. Please see full
Prescribing Information, including Boxed WARNINGS, and Medication Guide for
SPRAVATO® and discuss any questions you may have with your healthcare provider.

Download the Brochure


SPRAVATO® SIDE EFFECTS

Serious side effects of SPRAVATO® include feeling sleepy (sedation); feeling
disconnected from yourself, your thoughts, feelings and things around you
(dissociation); abuse and misuse; increased risk of suicidal thoughts and
behavior; increased blood pressure; problems with thinking clearly; and bladder
problems. For additional information on these serious side effects, please see
Important Safety Information in this brochure. These are not all the possible
side effects of SPRAVATO®.

Call your doctor for medical advice about side effects. You may report side
effects to FDA at 1-800-FDA-1088. Please see full Prescribing Information,
including Boxed WARNINGS, and Medication Guide for SPRAVATO® and discuss any
questions you may have with your healthcare provider. cp-79822v3 © Janssen
Pharmaceuticals, Inc.


SPRAVATO® MAY CAUSE SERIOUS SIDE EFFECTS INCLUDING:

See Full Prescribing Info
 * Increased blood pressure. SPRAVATO® can cause a temporary increase in your
   blood pressure that may last for about 4 hours after taking a dose. Your
   healthcare provider will check your blood pressure before taking SPRAVATO®
   and for at least 2 hours after you take SPRAVATO®. Tell your healthcare
   provider right away if you get chest pain, shortness of breath, sudden severe
   headache, change in vision, or seizures after taking SPRAVATO®.
 * Problems with thinking clearly. Tell your healthcare provider if you have
   problems thinking or remembering.
 * Bladder problems. Tell your healthcare provider if you develop trouble
   urinating, such as a frequent or urgent need to urinate, pain when urinating,
   or urinating frequently at night

In studies of patients with major depressive disorder and active suicidal
thoughts or actions, those who took and an oral antidepressant experienced a
greater reduction of depressive symptoms at 24 hours compared to those who
received a placebo plus an oral antidepressant.* Further reductions were seen
consistently through four weeks (25 days) of treatment, so it is important to
follow the treatment plan that you and your healthcare provider have made. Not
all patients will respond to SPRAVATO®.

It is not known if SPRAVATO® is safe and effective for use in preventing suicide
or in reducing suicidal thoughts or actions. SPRAVATO® is not for use in place
of hospitalization if your healthcare provider determines that hospitalization
is needed, even if improvement is experienced after the first dose of SPRAVATO®.

Ask your healthcare provider if SPRAVATO® may be right for you. SPRAVATO® is not
for use as a medicine to prevent or relieve pain (anesthetic). It is not known
if SPRAVATO® is safe or effective as an anesthetic medicine. It is not known if
SPRAVATO® is safe and effective in children.


THE MOST COMMON SIDE EFFECTS OF SPRAVATO® WHEN USED ALONG WITH AN ANTIDEPRESSANT
TAKEN BY MOUTH INCLUDE:

See Full Prescribing Info
 * Feeling disconnected from yourself, your thoughts, feelings and things around
   you
 * Dizziness
 * Nausea
 * Feeling sleepy
 * Decreased feeling of sensitivity (numbness)
 * Feeling anxious

 * Spinning sensation
 * Lack of energy
 * Increased blood pressure
 * Vomiting
 * Feeling drunk
 * Feeling very happy or excited


WHAT TO EXPECT

Visit SPRAVATO.com SPRAVATO® (esketamine) CIII nasal spray can only be
administered under the supervision of a healthcare provider at a treatment
center that is certified in the SPRAVATO® Risk Evaluation and Mitigation
Strategy (REMS) Program. As part of the REMS, a healthcare provider will discuss
the risks of sedation, dissociation, and abuse and misuse with you before
starting SPRAVATO®. You and a healthcare provider must complete a Patient
Enrollment Form for you to receive SPRAVATO® in a certified treatment center.


DISCUSS WITH YOUR HEALTHCARE PROVIDER BEFORE TAKING SPRAVATO®

SPRAVATO® is not for everyone. Talk to your healthcare provider about your full
medical history, including if you:

 * Have a history of abusing or being dependent on prescription or street drugs
 * Have a problem with alcohol
 * Are pregnant or planning to become pregnant

 * Are breastfeeding or planning to breastfeed
 * Take prescription or over-the-counter medicines
 * Take vitamins or herbal supplements


YOUR FIRST TREATMENT CENTER VISIT

Your healthcare provider will continue to be involved with your care during
SPRAVATO® treatment and will be available to answer questions or address
concerns as you undergo treatment.

Catalyst Psychiatry Can Help!

Your first visit to the certified SPRAVATO® treatment center will be a
consultation. The treatment center will:

 * Receive your medical information from your healthcare provider
 * Conduct its own assessment to determine if SPRAVATO® may be right for you
 * Verify your insurance information as part of the eligibility confirmation

If SPRAVATO® is recommended, the treatment center will build a treatment plan
with you and enroll you in the SPRAVATO® REMS Program.


SPRAVATO WITHME– THE SUPPORT PROGRAM THAT’S BY YOUR SIDE FROM THE START

SPRAVATO® is covered by most insurance and there are ways to help pay for it.

Learn More Today!


DO YOU STRUGGLE WITH TREATMENT-RESISTANT DEPRESSION?


THERE'S A DIFFERENT CHOICE TO TURN TO

Contact Catalyst Psychiatry to see if SPRAVATO® is right for you.
Contact Us Today

Catalyst Psychiatry empowers change within by looking at all aspects of you and
your unique situation. Our services include Counseling, Deep TMS, Medication
Management, Psychiatric Diagnosis & Treatment, Psychotherapy, and Genesight in
Corvallis, Oregon.

Facebook


SERVICES

 * Counseling
 * Deep TMS
 * GeneSight
 * Medication Management
 * Psychiatric Diagnosis & Treatment
 * Psychotherapy


RESOURCES

 * Office Policies
 * Privacy Policy
 * TMS Self Assessment


CONNECT

 * All Services
 * Careers
 * Contact Us
 * Patient Portal

 * (541) 730-4400
 * 2222 NW Lincoln Ave., Corvallis, OR


CATALYST PSYCHIATRY, LLC © ALL RIGHTS RESERVED


POWERED BY CLARK FIVE DESIGN